A phase I study of combination vaccine treatment of five therapeutic
epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. S
Hazama, Y Nakamura, H Takenouchi, N Suzuki, R Tsunedomi, Y Inoue, et al. J Transl Med. 2014; 10;12:63.
Phase I clinical study of multiple epitope peptide vaccine combined with
chemoradiation therapy in esophageal cancer patients. H Iinuma, R Fukushima, T Inaba, J Tamura, T Inoue, E
Ogawa, et al. J Transl Med. 2014; 3;12:84.
A phase ΙI study of five peptides combination with oxaliplatin-based
chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). S Hazama, Y Nakamura, H
Tanaka, K Hirakawa, K Tahara, R Shimizu, et al. J Transl Med. 2014; 30;12:108.
Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for
patients with metastatic colorectal cancer. Okuno K, Sugiura F, Inoue K, Sukegawa Y. Anticancer Res. 2014;
Predictive biomarkers for the outcome of vaccination of five therapeutic
epitope peptides for colorectal cancer. Hazama S, Takenouchi H, Tsunedomi R, Iida M, Suzuki N, Iizuka N, et
al. Anticancer Res. 2014; 34(8):4201-5.
A phase I clinical trial of vaccination with KIF20A-derived peptide in
combination with gemcitabine for patients with advanced pancreatic cancer. Suzuki N, Hazama S, Ueno T,
Matsui H, Shindo Y, Iida M, et al. J Immunother. 2014; 37(1):36-42.
Phase I clinical trial of multiple-peptide vaccination for patients with
advanced biliary tract cancer. Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, et al. J
Transl Med. 2014; 7;12:61.
Vaccination of biliary tract cancer patients with four peptides derived
from cancer-testis antigens. Aruga A. Oncoimmunology. 2013; 1;2(7)
Immunological responses to a multi-peptide vaccine targeting cancer-testis
antigens and VEGFRs in advanced pancreatic cancer patients. Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto
M. Oncoimmunology. 2013; 1;2(11)
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil
plus leucovorin for treatment of advanced or recurrent colorectal cancer. Matsushita N, Aruga A, Inoue Y,
Kotera Y, Takeda K, Yamamoto M. Oncol Rep. 2013; 29(3):951-9.
Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived
from KIF20A for patients with advanced pancreatic cancer. Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H.
J Transl Med. 2013; 16;11:291.
Multiple therapeutic peptide vaccines consisting of combined novel cancer
testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. Suzuki H,
Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, et al. J Transl Med. 2013; 11;11:97.
Phase I clinical trial of human vascular endothelial growth factor
receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Yoshimura K, Minami T, Nozawa
M, Uemura H. Br J Cancer. 2013; 2;108(6):1260-6.
Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis
Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract
Cancer. Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, et al. Clin Cancer Res. 2013;
Multicenter, phase II clinical trial of cancer vaccination for advanced
esophageal cancer with three peptides derived from novel cancer-testis antigens. K Kono, H Iinuma, Y Akutsu,
H Tanaka, N Hayashi, Y Uchikado, et al. J Transl Med. 2012; 9;10:141.
Cancer peptide vaccine therapy developed from oncoantigens identified
through genome-wide expression profile analysis for bladder cancer. W Obara, R Ohsawa, M Kanehira, R Takata,
T Tsunoda, K Yoshida, et al. Jpn J Clin Oncol. 2012; 42(7):591-600.
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for
human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. T
Masuzawa, Y Fujiwara, K Okada, A Nakamura, S Takiguchi, K Nakajima, et al. Int J Oncol. 2012;
Recent Advances in Active Specific Cancer Vaccine Treatment for Colorectal
Cancer. K Okuno, F Sugiura, K Itoh, K Yoshida, T Tsunoda, Y Nakamura, Curr Pharm Biotechnol. 2012;
Significant clinical response of advanced colon cancer to peptide vaccine
therapy: a case report. S Yasuda, I Tsuchiya, K Okada, A Tanaka, T Suzuki, S Sadahiro, et al. Tokai J Exp
Clin Med. 2012; 20;37(2):57-61.
Phase I clinical trial of a novel peptide vaccine in combination with
UFT/LV for metastatic colorectal cancer. K Okuno, F Sugiura, J Hida, T Tokoro, E Ishimaru, Y Sukegawa, et
al. Exp Ther Med. 2011; 2(1):73-79.
Vaccination with peptides derived from cancer-testis antigens in
combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic
esophageal squamous cell carcinoma. Iwahashi M, Katsuda M, Nakamori M, Nakamura M, Naka T, Ojima T, et al.
Cancer Sci. 2010; 101(12):2510-7.
Vaccination with multiple peptides derived from novel cancer‐testis
antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer. K Kono,
Y Mizukami, Y Daigo, A Takano, K Masuda, K Yoshida, et al. Cancer Sci. 2009; 100(8):1502-9.
Phase I clinical trial using peptide vaccine for human vascular
endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic
cancer. M Miyazawa, R Ohsawa, T Tsunoda, S Hirono, M Kawai, M Tani, et al. Cancer Sci. 2010; 101(2):433-9.
Detection of novel cancer‐testis antigen‐specific T‐cell responses in TIL,
regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma., Y Mizukami, K Kono, Y
Daigo, A Takano, T Tsunoda, Y Kawaguchi, et al. Cancer Sci. 2010; 101(2):433-9.
Identification of CDCA1‐derived long peptides bearing both CD4+ and CD8+
T‐cell epitopes: CDCA1‐specific CD4+ T‐cell immunity in cancer patients. Y Tomita, A Yuno, H Tsukamoto, S
Senju, S Yoshimura, R Osawa, et al. Int J Cancer. 2014; 15;134(2):352-66.
Identification of immunogenic LY6K long peptide encompassing both CD4+ and
CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease. Y Tomita, A
Yuno, H Tsukamoto, S Senju, Y Kuroda, M Hirayama, et al. Oncoimmunology. 2014; 27;3:e28100.
Identification of promiscuous KIF20A long peptides bearing both CD4+ and
CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Y Tomita, A
Yuno, H Tsukamoto, S Senju, Y Kuroda, M Hirayama, A Irie, et al. Clin Cancer Res. 2013; 15;19(16):4508-20.
Identification of HLA-A24-restricted novel T Cell epitope peptides derived
from P-cadherin and kinesin family member 20A. R Osawa, T Tsunoda, S Yoshimura, T Watanabe, M Miyazawa, M
Tani, et al. J Biomed Biotechnol. 2012; 2012:848042.
Identification of HLA-A2-restricted CTL epitopes of a novel
tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. K Imai, S Hirata, A Irie, S Senju, Y
Ikuta, K Yokomine, M Harao, M Inoue, et al. Br J Cancer. 2011; 18;104(2):300-7.
HLA‐A2‐restricted CTL epitopes of a novel lung cancer‐associated cancer
testis antigen, cell division cycle associated 1, can induce tumor‐reactive CTL. M Harao, S Hirata, A Irie,
S Senju, T Nakatsura, H Komori, Y Ikuta, et al. Int J Cancer. 2008; 1;123(11):2616-25.
Identification of human leukocyte antigen‐A24‐restricted epitope peptides
derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. T
Suda, T Tsunoda, Y Daigo, Y Nakamura, H Tahara. Cancer Sci. 2007; 98(11):1803-8
Inhibition of tumor growth with antiangiogenic cancer vaccine using
epitope peptides derived from human vascular endothelial growth factor receptor 1. Ishizaki H, Tsunoda T,
Wada S, Yamauchi M, Shibuya M, Tahara H. Clin Cancer Res. 2006; 1;12(19):5841-9.
Rationale for antiangiogenic cancer therapy with vaccination using epitope
peptides derived from human vascular endothelial growth factor receptor 2. Wada S, Tsunoda T, Baba T, Primus
FJ, Kuwano H, Shibuya M, et al. Cancer Res. 2005; 1;65(11):4939-46.
A novel oncoprotein RNF43 functions in an autocrine manner in colorectal
cancer. R Yagyu, Y Furukawa, YM Lin, T Shimokawa, T Yamamura, Y Nakamura, Int J Oncol. 2004; 25(5):1343-8.